• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2023.18066

Clinical relevance of pharmacogenetic testing of cytochrome P450 gene (CYP2C19) polymorphisms to personalize the selection of proton pump inhibitors

[Original research] [Clinical Pharmacology] [Pharmacology]
Vladimir Ivanovich Petrov; Anzhelika Viktorovna Ponomareva; Анна Михайловна Доценко; Olga Viktorovna Razvalyaeva; Irina Vyacheslavovna Ivakhnenko;

In the study examined the prevalence of genotypes of the polymorphic 681G/A locus (rs 4244285) and the G636A locus (rs 4986893) of the CYP2C19 gene among the population of the Volgograd region; assess the need for genotyping of this polymorphic locus in clinical practice. Genetic typing of CYP2C19*2 (681G>A), CYP2C19*3 (363G>A) was performed in 183 healthy volunteers aged 18 to 55 years living in Volgograd region. Statistical processing of the results was performed using MS Excel, Statistica 8.0, and GraphPad Prism 5.0. Genotyping of the 681G/A polymorphic locus of the CYP2C19 gene showed that the G/G genotype has the highest prevalence in the population – 76 % of people, the heterozygous G/A variant is observed less frequently – 20.3 % of respondents, 3.3 % had the A/A genotype. Another ratio was found when genotyping the G636A polymorphic locus of the CYP2C19 gene: G/G genotype was 97.82 %, G/A – 1.64 % of respondents, and only 0.54 % of participants had the A/A genotype. Thus, despite the predominance of extensive metabolizers in the population of people living in Volgograd region, there is a need for genotyping of polymorphic locus 681G/A (rs 4244285) and locus G636A (rs 4986893) of CYP2C19 gene in patients with acid-dependent diseases for personalization of PPI selection and its dose.

Download

References:
1. El Rouby N., Lima J. J., Johnson J. A. Proton pump inhibitors: from CYP2C19 pharmacogenetics to precision medicine. Expert Opin. Drug. Metab. Toxicol. 2018;14(4):447-460. https://doi.org/10.1080/17425255.2018.1461835
2. Shin J. M., Sachs G. Pharmacology of proton pump inhibitors. Curr. Gastroenterol. Rep. 2008;10(6):528-534. https://doi.org/10.1007/s11894-008-0098-4
3. Lin Y. A., Wang H., Gu Z. J., Wang W. J., Zeng X. Y. [et al.]. Effect of CYP2C19 Gene Polymorphisms on Proton Pump Inhibitor, Amoxicillin, and Levofloxacin Triple Therapy for Eradication of Helicobacter Pylori. Med. Sci. Monit.2017;23:2701-2707. https://doi.org/10.12659/msm.901514
4. Zhao X., Zhang Z., Lu F., Xiong M., Jiang L. [et al.]. Effects of CYP2C19 genetic polymorphisms on the cure rates of H. pylori in patients treated with the proton pump inhibitors: An updated meta-analysis. Front. Pharmacol.2022;13:938419. https://doi.org/10.3389/fphar.2022.938419
5. Arévalo Galvis A., Trespalacios Rangel A. A., Otero Regino W. Personalized therapy for Helicobacter pylori: CYP2C19 genotype effect on first-line triple therapy. Helicobacter. 2019;24(3):e12574. https://doi.org/10.1111/hel.12574
6. Gronich N., Lavi I., Lejbkowicz F., Pinchev M., Rennert G.Association of CYP2C19 Polymorphism With Proton Pump Inhibitors Effectiveness and With Fractures in Real-Life: Retrospective Cohort Study. Clin. Pharmacol. Ther.2022;111(5):1084-1092. https://doi.org/10.1002/cpt.2552
7. Fu J., Sun C. F., He H. Y., Ojha S. C., Shi H. [et al.]. The effect of CYP2C19 gene polymorphism on the eradication rate of Helicobacter pylori by proton pump inhibitors-containing regimens in Asian populations: a meta-analysis. Pharmacogenomics. 2021;22(13):859-879. https://doi.org/10.2217/pgs-2020-0127
8. Malfertheiner P., Megraud F., Rokkas T., Gisbert J. P., Liou J. M. [et al.]. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut. 2022:327745. https://doi.org/10.1136/gutjnl-2022-327745
9. Lazebnik L. B., Bordin D. S., Dehnich N. N., Kozlov R. S., Tryapyshko A. A. VII National recommendations for the diagnosis and treatment of diseases associated with Helicobacter pylori (VII Moscow Agreements. Methodological recommendations. Project. Moscow, 2021. (In Russ.). https://www.rnmot.ru/ru/library/clinical
10. Lima J. J., Thomas C. D., Barbarino J., Desta Z., Van Driest S. L. [et al.]. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin. Pharmacol. Ther.2021;109(6):1417-1423. https://doi.org/10.1002/cpt.2015
11. Qiao H. L., Hu Y. R., Tian X., Jia L. J., Gao N. [et al.]. Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype. Eur. J. Clin. Pharmacol. 2006;62(2):107-112. https://doi.org/10.1007/s00228-005-0063-1
12. Park S., Hyun Y. J., Kim Y. R., Lee J. H., Ryu S. [et al.]. Effects of CYP2C19 Genetic Polymorphisms on PK/PD Responses of Omeprazole in Korean Healthy Volunteers. J. Korean Med. Sci. 2017;32(5):729-736. https://doi.org/10.3346/jkms.2017.32.5.729
13. Harris D. M., Stancampiano F. F., Burton M. C., Moyer A. M., Schuh M. J. [et al.]. Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice. Dig. Dis. Sci. 2021;66(12):4120-4127. https://doi.org/10.1007/s10620-020-06814-1

Keywords: proton pump inhibitors, genetic polymorphism, CYP2C19, acid-dependent diseases